

## Reconciliation of results and studies included.

	Current (August, 2020) PMID <a href="#">32805168</a>	Giustozzi, May 2020 PMID <a href="#">31104194</a>	Fuentes, 2019 <sup>a</sup> PMID <a href="#">31685262</a>	Wongsaengsak, 2019 DOI <a href="#">10.1182/blood-2019-125473</a>	Brunetti, 2019 PMID <a href="#">31654194</a>
<b>Outcome(s)</b>					
<b>Venous thromboembolism recurrence</b>					
Effect size	OR: 0.59 (0.41-0.86) ↓	RR: 0.62 (0.43-0.91) ↓	OR: 0.48 (0.24-0.96) ↓	RR: 0.48 (0.26-0.87) ↓	RR: 0.56 (0.40-0.79) ↓
Heterogeneity	25%	30%	46%	56%	59%
<b>Major bleeding</b>					
Effect size	<b>OR:</b> 1.34 (0.83-2.18)	<b>RR:</b> 1.31 (0.83-2.08)	<b>OR:</b> 1.70 (1.04-2.78)	<b>RR:</b> 1.55 (0.79-3.04)	<b>RR:</b> 1.53 (0.95-2.47)
Heterogeneity	28%	23%	2%	29%	28%
Summary of important differences or findings	Included findings at 12 months for HOKUSAI VTE trial.				
<b>Studies included</b>					
Raskob (HOKUSAI-VTE), 2018 PMID <a href="#">29231094</a>	Yes*	Yes	Yes	Yes	Yes
Young (SELECT-D), 2018 PMID <a href="#">29746227</a>	Yes	Yes	Yes	Yes	Yes
McBane (ADAM-VTE), 2019 PMID <a href="#">28837207</a>	Yes	Yes	Yes	Yes	Yes
Agnelli (CaraVaggio), 2020 PMID <a href="#">32223112</a>	Yes	Yes	NA	NA	NA
<b>Notes:</b>					
* Outcomes reported at 12 months for HOKUSAI VTE trial were used in the current analysis.					

